| Non-Alcoholic Fatty Liver Disease |
1 |
1 |
| Biliary Disease |
0 |
0.8 |
| Metabolic Syndrome |
0 |
0.9 |
| Liver Biopsy |
0 |
0.98 |
| Diagnostic Liver Biopsy |
0 |
0.99 |
| Liver |
0 |
0.78 |
| Fatty Liver |
0 |
0.67 |
| Liver Disease |
0 |
0.67 |
| Biopsy |
0 |
0.97 |
| Blood |
0 |
0.96 |
| Nonalcoholic Steatohepatitis |
0 |
0.21 |
| Biomarker |
0 |
0.16 |
| Health Care Reform |
0 |
0.11 |
| Alcohol Use |
0 |
0.08 |
| Cirrhosis |
0 |
0.08 |
| Insurance |
0 |
0.08 |
| Metabolism |
0 |
0.08 |
| New York |
0 |
0.08 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.08 |
| Outpatient Clinic |
0 |
0.08 |
| Steatosis |
0 |
0.08 |
| Tissue |
0 |
0.08 |
| Virginia |
0 |
0.08 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.07 |
| HIV Infection |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |